scholarly journals Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure

2017 ◽  
Vol 4 (4) ◽  
pp. 614-622 ◽  
Author(s):  
Shuntaro Ikeda ◽  
Kiyotaka Ohshima ◽  
Shigehiro Miyazaki ◽  
Hisaki Kadota ◽  
Hideaki Shimizu ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure ◽  
Diuretic Response

Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease

2015 ◽  
Vol 31 (10) ◽  
pp. 1643-1649 ◽  
Author(s):  
Yusuke Uemura ◽  
Rei Shibata ◽  
Kenji Takemoto ◽  
Tomohiro Uchikawa ◽  
Masayoshi Koyasu ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Clinical Benefit ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure

scholarly journals The role of B-type natriuretic peptide in diagnosing acute decompensated heart failure in chronic kidney disease patients

2018 ◽  
Vol 14 (5) ◽  
pp. 1003-1009 ◽  
Author(s):  
Amer N. Kadri ◽  
Roop Kaw ◽  
Yasser Al-Khadra ◽  
Hasan Abumasha ◽  
Keyvan Ravakhah ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Natriuretic Peptide ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure

scholarly journals Comorbidities and Negative Prognostic Factors in Lebanese Patients Presenting with Acute Decompensated Heart Failure with Preserved Ejection Fraction: A Multicenter Retrospective Study

2021 ◽  
Vol 1 (1) ◽  
pp. 124-134
Author(s):  
Joseph El Khoury ◽  
Ronza Bachnak ◽  
Hiba El Assaad ◽  
Nahed Damaj ◽  
Jad Terro
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Retrospective Study ◽  
Kidney Disease ◽  
Ejection Fraction ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure ◽  
Preserved Ejection Fraction ◽  
Valvular Heart Diseases

Background: Congestive heart failure is responsible for repeated hospital admissions. It is classified into three types: (1) Heart Failure with reduced ejection fraction, (2) Heart failure with mid-range ejection fraction, and (3) Heart failure with preserved ejection fraction (HFpEF). It is essential to describe the risk factors of HFpEF patients' profiles as targeting them is crucial for management. Aim: Our retrospective study aims to identify the clinical and echocardiographic characteristics associated with HFpEF and its mortality among hospitalized patients with acute decompensated heart failure. Methods: 390 patients of all age groups presenting with acute heart failure decompensation at Mount Lebanon Hospital (MLH) and Middle East Institute of Health (MEIH, Bsalim) were recruited retrospectively between January 2014 and December 2016. We included 133 cases of HFpEF and collected data on each case including: baseline characteristics and comorbidities, electrocardiograms, laboratory studies, and echocardiographic parameters. Results: The 133 Lebanese patients having HFpEF were elderly (76 ± 10 years), with predominantly female gender (56%). Hypertension (87.96%) and diabetes (53.38%) were the most frequently reported comorbidities. The overall in-hospital mortality was 4.5%. Data was compared between living and deceased patients and the frequency of valvular heart disease (p=0.005) and chronic kidney disease (p=0.018) was significantly higher among deceased patients. Right ventricular (RV) dilation on echocardiography was significantly correlated with mortality. Elevated troponin, increased creatinine, hypochloremia, hyponatremia, and anemia were all lab markers associated with increased mortality (p<0.05). Conclusion: Patients with HFpEF represent 43.5% of all decompensated HF cases, with chronic kidney disease, valvular heart diseases, anemia and troponinemia, being the predominant risk factors for adverse clinical outcomes. HFpEF remains an enormous burden on cardiologists for appropriate evaluation, triage, and management.

scholarly journals Effects of early diuretic response to carperitide in acute decompensated heart failure treatment: A single-center retrospective study

PLoS ONE ◽  
2018 ◽  
Vol 13 (6) ◽  
pp. e0199263 ◽  
Author(s):  
Yoshitaka Okuhara ◽  
Masanori Asakura ◽  
Kohei Azuma ◽  
Yoshiyuki Orihara ◽  
Koichi Nishimura ◽  
...  
Keyword(s):  
Heart Failure ◽  
Retrospective Study ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure ◽  
Single Center ◽  
Heart Failure Treatment ◽  
Failure Treatment ◽  
Diuretic Response

scholarly journals Acute kidney disease after acute decompensated heart failure

2022 ◽  
Author(s):  
Jia-Jin Chen ◽  
Tao-Han Lee ◽  
George Kuo ◽  
Chieh-Li Yen ◽  
Shao-Wei Chen ◽  
...  
Keyword(s):  
Heart Failure ◽  
Kidney Disease ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure ◽  
Acute Kidney Disease

scholarly journals Effects of Metolazone Administration on Congestion, Diuretic Response and Renal Function in Patients with Advanced Heart Failure

2021 ◽  
Vol 10 (18) ◽  
pp. 4207
Author(s):  
Alberto Palazzuoli ◽  
Gaetano Ruocco ◽  
Paolo Severino ◽  
Luigi Gennari ◽  
Filippo Pirrotta ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Function ◽  
Acute Decompensated Heart Failure ◽  
Nyha Class ◽  
Decompensated Heart Failure ◽  
Advanced Heart Failure ◽  
Loop Diuretics ◽  
Reduced Ejection Fraction ◽  
Diuretic Response

Background: Advanced heart failure (HF) is a condition often requiring elevated doses of loop diuretics. Therefore, these patients often experience poor diuretic response. Both conditions have a detrimental impact on prognosis and hospitalization. Aims: This retrospective, multicenter study evaluates the effect of the addition of oral metolazone on diuretic response (DR), clinical congestion, NTproBNP values, and renal function over hospitalization phase. Follow-up analysis for a 6-month follow-up period was performed. Methods: We enrolled 132 patients with acute decompensated heart failure (ADHF) in advanced NYHA class with reduced ejection fraction (EF < 40%) taking a mean furosemide amount of 250 ± 120 mg/day. Sixty-five patients received traditional loop diuretic treatment plus metolazone (Group M). The mean dose ranged from 7.5 to 15 mg for one week. Sixty-seven patients continued the furosemide (Group F). Congestion score was evaluated according to the ESC recommendations. DR was assessed by the formula diuresis/40 mg of furosemide. Results: Patients in Group M and patients in Group F showed a similar prevalence of baseline clinical congestion (3.1 ± 0.7 in Group F vs. 3 ± 0.8 in Group M) and chronic kidney disease (CKD) (51% in Group M vs. 57% in Group F; p = 0.38). Patients in Group M experienced a better congestion score at discharge compared to patients in Group F (C score: 1 ± 1 in Group M vs. 3 ± 1 in Group F p > 0.05). Clinical congestion resolution was also associated with weight reduction (−6 ± 2 in Group M vs. −3 ± 1 kg in Group F, p < 0.05). Better DR response was observed in Group M compared to F (940 ± 149 mL/40 mgFUROSEMIDE/die vs. 541 ± 314 mL/40 mgFUROSEMIDE/die; p < 0.01), whereas median ΔNTproBNP remained similar between the two groups (−4819 ± 8718 in Group M vs. −3954 ± 5560 pg/mL in Group F NS). These data were associated with better daily diuresis during hospitalization in Group M (2820 ± 900 vs. 2050 ± 1120 mL p < 0.05). No differences were found in terms of WRF development and electrolyte unbalance at discharge, although Group M had a significant saline solution administration during hospitalization. Follow-up analysis did not differ between the group but a reduced trend for recurrent hospitalization was observed in the M group (26% vs. 38%). Conclusions: Metolazone administration could be helpful in patients taking an elevated loop diuretics dose. Use of thiazide therapy is associated with better decongestion and DR. Current findings could suggest positive insights due to the reduced amount of loop diuretics in patients with advanced HF.

Sign in / Sign up

Export Citation Format

Share Document